Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis

Kang, Jeehoon; Rizas, Konstantinos D.; Park, Kyung Woo ✉; Chung, Jaewook; van, den Broek Wout; Claassens, Daniel M. F.; Choo, Eun Ho; Aradi, Daniel [Aradi, Dániel (Kardiológia), szerző] Kardiológia Központ - Kardiológiai Tanszék (SE / AOK / K); Massberg, Steffen; Hwang, Doyeon; Han, Jung-Kyu; Yang, Han-Mo; Kang, Hyun-Jae; Chang, Kiyuk; ten, Berg Jur M.; Sibbing, Dirk; Koo, Bon-Kwon; Kim, Hyo-Soo

Angol nyelvű Szakcikk (Folyóiratcikk) Tudományos
Megjelent: EUROPEAN HEART JOURNAL 0195-668X 1522-9645 44 (15) pp. 1360-1370 2023
  • SJR Scopus - Cardiology and Cardiovascular Medicine: D1
Azonosítók
Szakterületek:
  • Szív és érrendszer
Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the standard treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). De-escalation of the potent P2Y12 inhibtor is an appealing concept to balance the ischaemic and bleeding risks after PCI. An individual patient data meta-analysis was performed to compare de-escalation versus standard DAPT in patients with ACS. Methods and results Electronic databases, including PubMed, Embase, and the Cochrane database, were searched to identify randomised clinical trials (RCTs) comparing the de-escalation strategy with the standard DAPT after PCI in patients with ACS. Individual patient-level data were collected from the relevant trials. The co-primary endpoints of interest were the ischaemic composite endpoint (a composite of cardiac death, myocardial infarction, and cerebrovascular events) and bleeding endpoint (any bleeding) at 1-year post-PCI. Four RCTs (the TROPICAL-ACS, POPular Genetics, HOST-REDUCE-POLYTECH-ACS, and TALOS-AMI trials) including 10 133 patients were analysed. The ischaemic endpoint was significantly lower in the patients assigned to the de-escalation strategy than in those assigned to the standard strategy (2.3% vs. 3.0%, hazard ratio [HR] 0.761, 95% confidence interval [CI] 0.597-0.972, log rank P = 0.029). Bleeding was also significantly lower in the de-escalation strategy group (6.5% vs. 9.1%, HR 0.701, 95% CI 0.606-0.811, log rank P < 0.001). No significant intergroup differences were observed in terms of all-cause death and major bleeding events. Subgroup analyses revealed that compared to guided de-escalation, unguided de-escalation had a significantly larger impact on bleeding endpoint reduction (P for interaction = 0.007); no intergroup differences were observed for the ischaemic endpoints. Conclusion In this individual patient data meta-analysis, DAPT-based de-escalation was associated with both decreased ischaemic and bleeding endpoints. Reduction in bleeding endpoints was more prominent for the unguided than the guided de-escalation strategy. Study registration number This study was registered in the PROSPERO (ID: CRD42021245477).
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2024-07-14 19:42